Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy

J Microbiol Immunol Infect. 2021 Feb 27:S1684-1182(21)00049-9. doi: 10.1016/j.jmii.2021.02.006. Online ahead of print.


We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.

PMID:33712404 | DOI:10.1016/j.jmii.2021.02.006